Radiomics Signature to Predict Prognosis in Early-Stage Lung Adenocarcinoma (≤3 cm) Patients with No Lymph Node Metastasis.
Li ZhangLv LvLin LiYan-Mei WangShuang ZhaoLei MiaoYan-Ning GaoMeng LiNing Wu
Published in: Diagnostics (Basel, Switzerland) (2022)
The radiomics signature has potential utility in estimating the prognosis of patients with pathological stage I lung adenocarcinoma (≤3 cm), potentially enabling a step forward in precision medicine.